The earnings call reflects a strong performance by BeOne, with significant revenue growth driven by BRUKINSA's market leadership and robust R&D advancements. However, challenges remain due to aggressive competition and potential regulatory impacts. Overall, the positive aspects significantly outweigh the challenges.

Company Guidance

During the Q2 2025 earnings call for BeOne Medicines, the company provided strong financial guidance and updates on their strategic priorities. The company reported a revenue of $1.3 billion for the second quarter, marking a 42% year-over-year increase. BRUKINSA, the leading BTK inhibitor in the U.S. market, contributed $950 million to the global revenue, showcasing a 49% year-over-year growth. The company's gross margin improved to approximately 87%, attributed to favorable product mix and production cost efficiencies. The financial guidance for the full fiscal year 2025 was updated, with total revenue expectations ranging between $5 billion and $5.3 billion. The operating expenses are projected to remain between $4.1 billion and $4.4 billion, with a commitment to achieving positive GAAP operating income and generating positive free cash flow. The company also highlighted several upcoming R&D milestones, including global filings and pivotal data readouts for their key pipeline assets. Overall, BeOne Medicines emphasized their robust execution, strong market positioning, and continued focus on innovation and growth across their oncology portfolio.

Significant Revenue Growth

BeOne's revenue reached $1.3 billion, representing a 42% year-on-year growth.

BRUKINSA's Market Leadership

BRUKINSA cemented itself as the #1 BTK inhibitor in the U.S. market with global revenues growing 49% year-over-year.

Strong Financial Performance

Net income reached $94 million with diluted earnings per ADS of $0.84, and non-GAAP net income was $253 million, reflecting a $230 million increase from the previous year.

R&D and Pipeline Progress

Significant milestones achieved with over 60 abstracts presented and multiple Phase III trials initiated.

Global Expansion and Market Penetration

Revenue growth was seen across all key regions, including 43% year-over-year growth in the U.S. and 87% in Europe.

BeiGene Ltd (HK:6160) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

HK:6160 Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	0.45 / -	-0.688	―	―	―
Aug 28, 2025	2025 (Q2)	0.25 / 0.55	-0.69	179.57% (+1.24)	―	―
May 07, 2025	2025 (Q1)	-0.38 / 0.00	-1.449	―	―	―
Mar 27, 2025	2024 (Q4)	-0.61 / -0.85	-2.124	59.75% (+1.27)	―	―
Nov 12, 2024	2024 (Q3)	-0.67 / -0.69	1.208	-156.95% (-1.90)	―	―
Aug 27, 2024	2024 (Q2)	-1.31 / -0.69	-2.185	68.42% (+1.50)	―	―
May 08, 2024	2024 (Q1)	-1.86 / -1.45	-2.016	28.13% (+0.57)	―	―
Feb 26, 2024	2023 (Q4)	-2.10 / -2.12	-2.589	17.96% (+0.46)	―	―
Nov 09, 2023	2023 (Q3)	-2.04 / 1.21	-3.254	137.12% (+4.46)	―	―
Aug 25, 2023	2023 (Q2)	-2.02 / -2.19	-3.357	34.91% (+1.17)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

HK:6160 Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 28, 2025	HK$178.70	HK$177.20	-0.84%
May 07, 2025	HK$153.20	HK$141.00	-7.96%
Mar 27, 2025	HK$151.70	HK$159.60	+5.21%
Nov 12, 2024	HK$125.20	HK$121.80	-2.72%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does BeiGene Ltd (HK:6160) report earnings?

BeiGene Ltd (HK:6160) is schdueled to report earning on Nov 06, 2025, TBA (Confirmed).

What is BeiGene Ltd (HK:6160) earnings time?

BeiGene Ltd (HK:6160) earnings time is at Nov 06, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of BeiGene Ltd stock?

The P/E ratio of BeiGene Ltd is N/A.

What is HK:6160 EPS forecast?

HK:6160 EPS forecast for the fiscal quarter 2025 (Q3) is 0.45.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing